INVO Fertility, Inc.IVF

INVO Fertility, Inc. filed an S-1 on 24 July 2026 to list its common shares, but the company’s own filings show it is still burning more cash than it earns, with revenue of $2.0 million for the quarter ending 31 March 2026 offset by a $5.5 million net loss and negative $1.9 million in operating cash flow. The company calls itself a fertility-services technology outfit, yet its only named device innovation, INVOcell, debuted six years ago and no new FDA clearances are mentioned in the latest 10-Q. The glossy pitch touts “expanding access,” yet the company’s working capital deficit and thin liquidity suggest the clinic floor is where the expansion is happening, not the trading floor.

INVO describes its core offering as a suite of assisted-reproduction services delivered through clinics, including in vitro fertilisation and the intravaginal culture device INVOcell. The June 2026 press release trumpets a 30 percent year-on-year jump in services revenue to $1.3 million in Q1 2026, yet the contemporaneous 10-Q records a net loss of $5.5 million for the same period. The gap between the marketing copy and the filed numbers is the clearest fact in the file. The company’s 10-Q for the quarter ending 31 March 2026 also shows $24.7 million in total assets against $9.6 million in liabilities, giving it $15.0 million in shareholders’ equity and a cash-burn profile that outpaces collections.

The DEF 14A dated 23 June 2026 invites investors to review the company’s Code of Conduct on its website and boasts an “open and engaged board,” yet the same filing contains no FDA clearances beyond the six-year-old INVOcell. The company’s strategy has quietly shifted from device-centric marketing to clinic-centric services, yet the latest filings still treat the device as the headline act. The 8-K filed on 24 July 2026 adds that the principal market for the shares will not meet “eligible market” standards on the closing date, implying early buyers will receive a 15 percent haircut baked into the purchase price. That is a liquidity safeguard wrapped inside an IPO wrapper.

There is The source-change rail is filing/source-led and does not use chart-derived signals. Chart context is available separately on this page through the Atlas chart snapshot or TradingView route where available. The only concrete market mechanism disclosed is the 85 percent valuation floor applied to the IPO price, which functions as a liquidity discount rather than a trading level. (source: INVO 8-K, 2026-07-24, https://www.sec.gov/Archives/edgar/data/1417926/000149315226034616/form8-k.htm)

What changed this week: INVO filed an S-1 to list its shares, disclosed a 15 percent liquidity discount for early buyers, and reiterated its shift from device marketing to clinic services, all while the latest 10-Q shows continued cash-burn. What remains unproven: any new FDA clearance after 2020, a clear path to sustained profitability, or a principal market that meets “eligible” standards on closing day. Evidence that would deepen the file next: a quarterly filing showing cash-basis profitability, an FDA clearance for a new device, or confirmation that the principal market qualifies as “eligible” on the closing date.